vs

Side-by-side financial comparison of WESTERN ALLIANCE BANCORPORATION (WAL) and DENTSPLY SIRONA Inc. (XRAY). Click either name above to swap in a different company.

WESTERN ALLIANCE BANCORPORATION is the larger business by last-quarter revenue ($1.0B vs $961.0M, roughly 1.1× DENTSPLY SIRONA Inc.). WESTERN ALLIANCE BANCORPORATION runs the higher net margin — 18.6% vs -15.2%, a 33.8% gap on every dollar of revenue. On growth, WESTERN ALLIANCE BANCORPORATION posted the faster year-over-year revenue change (31.0% vs 6.2%). Over the past eight quarters, WESTERN ALLIANCE BANCORPORATION's revenue compounded faster (14.9% CAGR vs 0.4%).

Western Alliance Bancorporation is a regional bank holding company headquartered in Phoenix. It is on the list of largest banks in the United States and is ranked 97th on the Forbes list of America's Best Banks.

Dentsply Sirona Inc. is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. It has factories in 21 countries. The present company is largely the result of a merger in 1993 in which Gendex Corporation acquired Dentsply International Inc. for $590 million.

WAL vs XRAY — Head-to-Head

Bigger by revenue
WAL
WAL
1.1× larger
WAL
$1.0B
$961.0M
XRAY
Growing faster (revenue YoY)
WAL
WAL
+24.8% gap
WAL
31.0%
6.2%
XRAY
Higher net margin
WAL
WAL
33.8% more per $
WAL
18.6%
-15.2%
XRAY
Faster 2-yr revenue CAGR
WAL
WAL
Annualised
WAL
14.9%
0.4%
XRAY

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
WAL
WAL
XRAY
XRAY
Revenue
$1.0B
$961.0M
Net Profit
$189.2M
$-146.0M
Gross Margin
46.1%
Operating Margin
-14.5%
Net Margin
18.6%
-15.2%
Revenue YoY
31.0%
6.2%
Net Profit YoY
-5.0%
66.0%
EPS (diluted)
$1.65
$-0.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
WAL
WAL
XRAY
XRAY
Q1 26
$1.0B
Q4 25
$980.9M
$961.0M
Q3 25
$938.2M
$904.0M
Q2 25
$845.9M
$936.0M
Q1 25
$778.0M
$879.0M
Q4 24
$838.4M
$905.0M
Q3 24
$823.1M
$951.0M
Q2 24
$771.8M
$984.0M
Net Profit
WAL
WAL
XRAY
XRAY
Q1 26
$189.2M
Q4 25
$286.1M
$-146.0M
Q3 25
$253.4M
$-427.0M
Q2 25
$230.4M
$-45.0M
Q1 25
$199.1M
$20.0M
Q4 24
$216.9M
$-430.0M
Q3 24
$199.8M
$-494.0M
Q2 24
$193.6M
$-4.0M
Gross Margin
WAL
WAL
XRAY
XRAY
Q1 26
Q4 25
46.1%
Q3 25
48.8%
Q2 25
52.4%
Q1 25
53.0%
Q4 24
49.3%
Q3 24
52.1%
Q2 24
51.9%
Operating Margin
WAL
WAL
XRAY
XRAY
Q1 26
Q4 25
36.3%
-14.5%
Q3 25
33.4%
-24.1%
Q2 25
34.4%
-13.7%
Q1 25
31.7%
7.2%
Q4 24
30.9%
-56.2%
Q3 24
30.6%
-48.6%
Q2 24
32.1%
5.1%
Net Margin
WAL
WAL
XRAY
XRAY
Q1 26
18.6%
Q4 25
29.2%
-15.2%
Q3 25
27.0%
-47.2%
Q2 25
27.2%
-4.8%
Q1 25
25.6%
2.3%
Q4 24
25.9%
-47.5%
Q3 24
24.3%
-51.9%
Q2 24
25.1%
-0.4%
EPS (diluted)
WAL
WAL
XRAY
XRAY
Q1 26
$1.65
Q4 25
$2.59
$-0.74
Q3 25
$2.28
$-2.14
Q2 25
$2.07
$-0.22
Q1 25
$1.79
$0.10
Q4 24
$1.94
$-2.09
Q3 24
$1.80
$-2.46
Q2 24
$1.75
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
WAL
WAL
XRAY
XRAY
Cash + ST InvestmentsLiquidity on hand
$326.0M
Total DebtLower is stronger
$4.3B
$2.3B
Stockholders' EquityBook value
$7.9B
$1.3B
Total Assets
$98.9B
$5.4B
Debt / EquityLower = less leverage
0.54×
1.70×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
WAL
WAL
XRAY
XRAY
Q1 26
Q4 25
$326.0M
Q3 25
$363.0M
Q2 25
$359.0M
Q1 25
$398.0M
Q4 24
$272.0M
Q3 24
$296.0M
Q2 24
$279.0M
Total Debt
WAL
WAL
XRAY
XRAY
Q1 26
$4.3B
Q4 25
$1.4B
$2.3B
Q3 25
$2.9B
Q2 25
$2.9B
Q1 25
$1.6B
Q4 24
$2.4B
$1.7B
Q3 24
$1.4B
Q2 24
$436.0M
Stockholders' Equity
WAL
WAL
XRAY
XRAY
Q1 26
$7.9B
Q4 25
$7.7B
$1.3B
Q3 25
$7.4B
$1.5B
Q2 25
$7.1B
$2.0B
Q1 25
$6.9B
$2.0B
Q4 24
$6.7B
$1.9B
Q3 24
$6.7B
$2.5B
Q2 24
$6.3B
$3.1B
Total Assets
WAL
WAL
XRAY
XRAY
Q1 26
$98.9B
Q4 25
$92.8B
$5.4B
Q3 25
$91.0B
$5.7B
Q2 25
$86.7B
$6.1B
Q1 25
$83.0B
$6.0B
Q4 24
$80.9B
$5.8B
Q3 24
$80.1B
$6.6B
Q2 24
$80.6B
$6.9B
Debt / Equity
WAL
WAL
XRAY
XRAY
Q1 26
0.54×
Q4 25
0.18×
1.70×
Q3 25
0.39×
Q2 25
0.41×
Q1 25
0.23×
Q4 24
0.36×
0.90×
Q3 24
0.21×
Q2 24
0.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
WAL
WAL
XRAY
XRAY
Operating Cash FlowLast quarter
$101.0M
Free Cash FlowOCF − Capex
$60.0M
FCF MarginFCF / Revenue
6.2%
Capex IntensityCapex / Revenue
4.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$104.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
WAL
WAL
XRAY
XRAY
Q1 26
Q4 25
$-2.7B
$101.0M
Q3 25
$-597.4M
$79.0M
Q2 25
$-357.7M
$48.0M
Q1 25
$-1.7B
$7.0M
Q4 24
$-2.7B
$87.0M
Q3 24
$-1.1B
$141.0M
Q2 24
$-745.8M
$208.0M
Free Cash Flow
WAL
WAL
XRAY
XRAY
Q1 26
Q4 25
$60.0M
Q3 25
$40.0M
Q2 25
$16.0M
Q1 25
$-12.0M
Q4 24
$36.0M
Q3 24
$98.0M
Q2 24
$156.0M
FCF Margin
WAL
WAL
XRAY
XRAY
Q1 26
Q4 25
6.2%
Q3 25
4.4%
Q2 25
1.7%
Q1 25
-1.4%
Q4 24
4.0%
Q3 24
10.3%
Q2 24
15.9%
Capex Intensity
WAL
WAL
XRAY
XRAY
Q1 26
Q4 25
4.3%
Q3 25
4.3%
Q2 25
3.4%
Q1 25
2.2%
Q4 24
5.6%
Q3 24
4.5%
Q2 24
5.3%
Cash Conversion
WAL
WAL
XRAY
XRAY
Q1 26
Q4 25
-9.36×
Q3 25
-2.36×
Q2 25
-1.55×
Q1 25
-8.31×
0.35×
Q4 24
-12.64×
Q3 24
-5.35×
Q2 24
-3.85×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

WAL
WAL

Segment breakdown not available.

XRAY
XRAY

Essential Dental Solutions$372.0M39%
Equipment And Instruments$160.0M17%
Implants And Prosthetics$150.0M16%
CADCAM$139.0M14%
Wellspect Healthcare$88.0M9%
Orthodontics$52.0M5%

Related Comparisons